Plain-English translation of NCT07483073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two experimental approaches to treating moderately to severely active ulcerative colitis or Crohn's disease. The main medication being studied is called mirikizumab, which is given as an intravenous infusion in the first phase and then as a subcutaneous injection (under the skin) if you respond well. A second group will test combining mirikizumab with another oral medication called during the first phase, then continuing with mirikizumab alone if treatment is working.
Many people with ulcerative colitis or Crohn's disease don't respond well enough to current treatments, and some develop intolerance to them. This trial exists to find new medication options that could help those patients achieve better control of their disease and reduce symptoms.
You likely qualify if…
You likely don't qualify if…
You would be in the study for at least 62 weeks (about 14 months). In the first phase, you would receive the study medication either as an IV infusion or as a combination of an oral pill and IV infusion, depending on which group you're assigned to. If your disease improves, you would move to the second phase and switch to receiving the medication as an injection under your skin. Throughout the study, you would have regular visits for check-ups, blood tests, and possibly an endoscopy to monitor how well the treatment is working.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States